• Produktbild: Biological Response Modifiers in Human Oncology and Immunology
  • Produktbild: Biological Response Modifiers in Human Oncology and Immunology
Band 166

Biological Response Modifiers in Human Oncology and Immunology

Fr. 143.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

21.11.2012

Herausgeber

Andor Szentivanyi

Verlag

Springer Us

Seitenzahl

320

Maße (L/B/H)

25.4/17.8/1.9 cm

Gewicht

634 g

Auflage

Softcover reprint of the original 1st ed. 1983

Sprache

Englisch

ISBN

978-1-4757-1412-8

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

21.11.2012

Herausgeber

Andor Szentivanyi

Verlag

Springer Us

Seitenzahl

320

Maße (L/B/H)

25.4/17.8/1.9 cm

Gewicht

634 g

Auflage

Softcover reprint of the original 1st ed. 1983

Sprache

Englisch

ISBN

978-1-4757-1412-8

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Weitere Artikel finden Sie in

  • Produktbild: Biological Response Modifiers in Human Oncology and Immunology
  • Produktbild: Biological Response Modifiers in Human Oncology and Immunology
  • I. Introduction.- Immunostimulation in Cancer Patients.- II. Biological Response Modifiers Derived from Leukocytes.- Interferons: Several Questions and Few Answers.- Interferon Hybrids: Prospects for Therapy.- Immunoregulation by Lymphokines: Immune Interferon and Lymphotoxin Induction of Lymphokine Activity in Human Peripheral Blood Leukocyte Cultures.- Monoclonal Antibodies as Anticancer Agents.- Treatment of A Murine Leukemia with Chlorambucil Bound Monoclonal Antibodies.- Immune Response in Strain 2 Guinea Pigs to the Syngeneic L2C Leukemia.- Diminished Synthesis of Immunoglobulins by Lymphocytes of Patients Treated with Thymosin (TFX) and Cyclophosphamide.- Protective Activity of Thymosin ?1 Against Tumor Progression in Immunosuppressed Mice.- Effect of Thymostimulin on Human Lymphocyte Adenosine Deaminase and Purine Nucleoside Phosphorylase Activities: Physiological and Therapeutic Effects.- Interleukins in Experimental Autoimmune Disease.- III. Biological Response Modifiers Derived from Microorganisms.- Muramyl Dipeptides: Prospect for Cancer Treatments and Immunostimulation.- Clinical Phase I Investigation of Intravenous Oil Attached Mycobacterial Components as Immunotherapeutic Agents.- Immunomodulating Effects of a Short-Term Oral Treatment with C 1821 in Untreated Cancer Patients: A Controlled Study.- Clinical Efficacy of Lentinan on Neoplastic Diseases.- Preclinical Evaluation of Lentinan in Animal Models.- Immunomodulation by Small Molecular Weight Bacterial Products.- Human Macrophages May Normally be “Primed” For a Strong Oxygen Radical Response.- IV. Synthetic Biological Response Modifiers.- Sodium Diethyldithiocarbamate (Imuthiol) and Cancer.- Isoprinosine and NPT 15392: Immunomodulation and Cancer.- Immunomodulation by NPT 15392 in Cancer Patients Under Chemotherapy.- Effect of Chronic Administration of a Synthetic Aromatic Retinoid (Ro 10-9359) on the Development of Lung Squamous Metaplasia and Epidermoid Cancer in Rats.- A Feasibility Study to Determine If Microbicidal Activity Can Be Measured in Dexamethasone-Treated Macrophage Cultures.- V. Acquired Immunodeficiency Syndrome.- Immunological Studies of Male Homosexuals With the Prodrome of the Acquired Immunodeficiency Syndrome (AIDS).- A Longitudinal Study of a Patient with Acquired Immunodeficiency Syndrome Using T Cell Subset Analysis.- VI. Workshop Summaries.- Clinical Evaluation of Immunomodulating Agents in Cancer with Emphasis on New Approaches.- Animal Tumor Models for Evaluating Chemically Defined Immunomodulators.